BEVERLY, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), an emerging
biopharmaceutical company, is pleased to announce to shareholders, and the public at large, that the company name is changing to
Innovation Pharmaceuticals Inc. (IPI) and it has received a new Committee on Uniform Securities Identification Procedures (CUSIP)
number of 45782D 100.
Innovation Pharmaceuticals more accurately describes the innovative nature of our first-in-class pipeline of mid-stage drug
candidates. These changes will have no impact on the marketability of the Company’s securities, or the ability to trade the common
stock through brokerage firms. Stockholders of the Company are not required to exchange their stock certificates in connection with
the name change.
The Company’s common stock will continue to trade under stock symbol “CTIX” on OTCQB until market close on June 8, 2017. Trading
on the OTCQB under the new Innovation Pharmaceuticals name and ticker symbol “IPIX” will begin at market open on June 9, 2017.
The Company’s new website address will change to www.IPharmInc.com. In the interim, the Company will maintain www.cellceutix.com.
The name change will be discussed at the upcoming live shareholder and investor conference call, to be held on Thursday, June 8,
2017, at 11am EDT. Senior Company management will be responding to recently posed questions submitted by email. Live call-in
questions will also be addressed.
Below are call-in details for the conference call:
Title: Innovation Pharmaceuticals Shareholder and Investor Conference Call
Presentation Type: Audio Webcast
Event Date: Thursday, June 8, 2017, at 11am EDT
Call-in Numbers: 866-682-6100 / 862-255-5401
Web Event Link: http://www.investorcalendar.com/event/15776
About the Company
Headquartered in Beverly, Massachusetts, Cellceutix Corporation, to become Innovation Pharmaceuticals Inc. (IPI), will be
publicly-traded under the company symbol “IPIX”. The Company is a clinical stage biopharmaceutical company developing innovative
therapies in multiple diseases. The Company believes it has a world-class portfolio of first-in-class lead drug candidates and is
now advancing them toward market approval, while actively seeking strategic partnerships. The Company’s psoriasis drug candidate
Prurisol completed a Phase 2 trial and the Company more recently launched a Phase 2b study. Prurisol is a small molecule that acts
through immune modulation and PRINS reduction. The Company’s anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical
trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and the Company has
commenced a Phase 2 study. In the laboratory, Kevetrin has been shown to induce activation of p53, often referred to as the
“Guardian Angel Gene” due to its crucial role in controlling cell mutations. Brilacidin, a defensin mimetic compound, has shown in
an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. The Company is
in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of oral mucositis in patients with head and
neck cancer; interim results have shown a marked reduction in the incidence of severe oral mucositis (WHO Grade ≥ 3). The Company’s
lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI.
Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing
regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria
(“superbugs”). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first
two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of
Inflammatory Bowel Disease (IBD). The Company has formed research collaborations with world-renowned research institutions in the
United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna.
More information is available on the Company website at www.IPharmInc.com.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning projected
timelines for the initiation and completion of clinical trials, our future drug development plans, other statements regarding
future product developments, including with respect to specific indications, and any other statements which are other than
statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company’s actual
results and experience to differ materially from anticipated results and expectations expressed in these forward-looking
statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,”
“hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among
other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the
Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development;
including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that the Company’s compounds may
not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United
States or elsewhere. A more complete description of these risk factors is included in the Company’s filings with the Securities and
Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to
release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or
circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by
applicable law or regulation.
INVESTOR AND MEDIA CONTACT Cellceutix Corporation Leo Ehrlich info@cellceutix.com
